Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**6-hydroxydopamine + rotenone** refers to the co-administration or co-application of two neurotoxic small molecules. **6-hydroxydopamine (6-OHDA)** is a neurotoxin structurally related to dopamine, which enters cells via dopamine or norepinephrine transporters and is used to selectively destroy catecholaminergic neurons. Its mechanism involves inhibition of mitochondrial complex I and IV, formation of reactive semiquinone intermediates, and production of reactive oxygen species (ROS). **Rotenone** is a highly lipophilic mitochondrial complex I inhibitor, commonly used as an insecticide and pesticide, as well as a research compound for modeling Parkinson’s disease and other neurodegenerative disorders. Rotenone enters cells passively and causes mitochondrial dysfunction by irreversible inhibition of complex I, leading to increased ROS and cell death. The combination is widely used experimentally to model mitochondrial dysfunction and oxidative stress relevant to neurodegenerative diseases such as Parkinson’s disease[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-hydroxydopamine + rotenone.